Competitive Price for Factory Wholesale Organic Intermediate BMK Pmk Powder 1-Propanol, 2-Methyl-2-[ (phenylmethylene) Amino]- CAS 22563-90-2

“Quality very first, Honesty as base, Sincere assistance and mutual profit” is our idea, in an effort to create consistently and pursue the excellence for Competitive Price for Factory Wholesale Organic Intermediate BMK Pmk Powder 1-Propanol, 2-Methyl-2-[ (phenylmethylene) Amino]- CAS 22563-90-2, High quality would be the key factor for that organization to stand out from other competitors. Seeing is Believing, want more information? Just trial on its items!
“Quality very first, Honesty as base, Sincere assistance and mutual profit” is our idea, in an effort to create consistently and pursue the excellence for China Pharmaceutical Intermediates and Agrochemical Intermediates, To get more information about us as well as see all our merchandise, please visit our website. To get more information please feel free to allow us to know. Thank you very much and wish your business always be great!

3′-Amino-2′-hydroxy-[1,1'-bipheny]-3-carboxylic acid is used as the intermediate of Eltrombopag .
Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is also the first drug approved by the US FDA for the treatment of AA in recent 30 years.
In december2012, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC), so that hepatitis C patients with poor prognosis due to low platelet count can start and maintain interferon based standard therapy for liver diseases. On february3,2014, GlaxoSmithKline announced that the FDA granted the breakthrough treatment drug qualification of Eltrombopag for the treatment of hemopenia in patients with severe chemicalbook aplastic anemia (SAA) who did not fully respond to immunotherapy. On August 24, 2015, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in adults and children aged 1 year and over with chronic immune thrombocytopenia (ITP) who have insufficient response to corticosteroids, immunoglobulins or splenectomy. On january4,2018, Eltrombopag was approved to be listed in China for the treatment of primary immune thrombocytopenia (ITP).

“Quality very first, Honesty as base, Sincere assistance and mutual profit” is our idea, in an effort to create consistently and pursue the excellence for Competitive Price for Factory Wholesale Organic Intermediate BMK Pmk Powder 1-Propanol, 2-Methyl-2-[ (phenylmethylene) Amino]- CAS 22563-90-2, High quality would be the key factor for that organization to stand out from other competitors. Seeing is Believing, want more information? Just trial on its items!
Competitive Price for China Pharmaceutical Intermediates and Agrochemical Intermediates, To get more information about us as well as see all our merchandise, please visit our website. To get more information please feel free to allow us to know. Thank you very much and wish your business always be great!